Skip to main content
Title
Manager of Pharmacoepidemiology
Area of Study/Expertise
Epidemiology, Clinical Safety and Pharmacovigilance
Office Location
Daiichi Sankyo, Inc.
Phone Number
(862) 341-7698
Email
priyanka.yalamanchili@daiichisankyo.com

Priyanka Yalamanchili, PharmD, MS, RPh

Present Trainees

About

Priyanka Yalamanchili graduated from Rutgers University with a Doctor of Pharmacy (PharmD)
degree in 2021 and Master of Science (MS) degree in Epidemiology with a concentration in
Pharmacoepidemiology in 2024. She completed her post-doctoral fellowship in
Pharmacoepidemiology with Rutgers Institute for Pharmaceutical Industry Fellowships and
Daiichi Sankyo. During her fellowship, she held an adjunct faculty position with the Ernest
Mario School of Pharmacy at Rutgers University. She is currently a manager of
pharmacoepidemiology at Daiichi Sankyo.

Research Profile

Pharmacoepidemiology, Oncology, Pediatrics, Pharmacovigilance

Selected Publications

  1. Yalamanchili P, Lee LY, Bushnell G, Mannion ML, Dave CV, Horton DB. Trends in
    New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis
    Among Commercially Insured Children in the United States from 2001-2022. Arthritis
    Rheumatol. 2024. doi:10.1002/art.43041
  2. Yalamanchili P, Henderson M, Wang E, Salas M. Adverse Events in Patients Treated for
    Colorectal Cancer in Published Phase III Clinical Trials: A Systematic Review and Meta-
    Analysis. J Compr Cancer Res. 2024;4:100017.
  3. Khasraw M, Yalamanchili P, Santhanagopal A, et al. Clinical Management of Patients
    with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic
    Alterations: A Systematic Literature Review. Adv Ther. 2024;41(5):1815-1842.
    doi:10.1007/s12325-024-02799-9
  4. Henderson M, Yalamanchili P, Drinkwater C, et al. Perceptions, Experiences, and
    Behaviors of Patients and their Caregivers with Gastric and Gastroesophageal Cancer
    Treated with or without Trastuzumab Deruxtecan in the United States. Am J Health
    Behav. 2024. doi:10.5993/AJHB.48.5.18
  5. Wang E, Henderson M, Yalamanchili P, et al. Potential biomarkers in breast cancer drug
    development: application of the biomarker qualification evidentiary framework. Biomark
    Med. 2024;18(6):265-277. doi:10.2217/bmm-2023-0048
  6. Salas M, Gossell-Williams M, Yalamanchili P, et al. The Use of Biomarkers in
    Pharmacovigilance: A Systematic Review of the Literature. Biomark Insights.
    2023;18:11772719231164528. doi:10.1177/11772719231164528
  7. Salas M, Petracek J, Yalamanchili P, et al. The Use of Artificial Intelligence in
    Pharmacovigilance: A Systematic Review of the Literature. Pharmaceut Med.
    2022;36(5):295-306. doi:10.1007/s40290-022-00441-z